Loading List

The Heir Hunters®

halo top stock price

All Deals. Export data to Excel for your own analysis. Looking for new stock ideas? Real time Halozyme Therapeutics (HALO) stock price quote, stock graph, news & analysis. The P/E ratio of Halozyme Therapeutics is 254.13, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.86. Sale. A Halo Top serving has 240 … It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Deals. Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances, Chief of Staff to the CEO, VP & Head of Project Management, Start Your Risk-Free Trial Subscription Here, 3 Pandemic Perma-Winners For Your Portfolio, 3 Retail Stocks to Buy Ahead of Earnings This Week, It’s Time To Buy Patterson Companies (NASDAQ:PDCO) 3.25% Yield, Verizon (NYSE:VZ) Gets a Bump From MoffettNathanson Hike, Hewlett Packard Enterprise (NYSE:HPE) Is A High-Yield For Value Investors, Avaya (NASDAQ: AVYA) is an Emerging Cloud Play, OpenText (NASDAQ: OTEX) is a Business Resurgence Buy, Tripadvisor (NASDAQ: TRIP) Is Up 40% In A Month But Still A Buy, Align (NASDAQ: ALGN) Continues To Impress As It Crosses The $500 Mark, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, Receive Analysts' Upgrades and Downgrades Daily. Halo Top generated $132.4 million in sales last year, according to data from IRI. Include out of stock. Halozyme Therapeutics has a market capitalization of $5.50 billion and generates $195.99 million in revenue each year. This is a signs that BULLS are attempting to "absorb" supply. Company insiders that own Halozyme Therapeutics stock include Connie Matsui, Dimitrios Chondros, Helen Torley, James M Daly, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre. halo top stock are also included in the list of such companies. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. The official website for Halozyme Therapeutics is www.halozyme.com. Include out of stock. View which stocks are hot on social media with MarketBeat's trending stocks report. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. How to buy halo stock price? Type. Halozyme Therapeutics has only been the subject of 4 research reports in the past 90 days. Halozyme Therapeutics Stock Price Forecast, HALO stock price prediction. View Halozyme Therapeutics' earnings history. According to analysts' consensus price target of $34.91, Halozyme Therapeutics has a forecasted downside of 14.1% from its current price of $40.66. 1 out of 5 & up & up. © American Consumer News, LLC dba MarketBeat® 2010-2020. Halozyme Therapeutics has received a consensus rating of Buy. View insider buying and selling activity for Halozyme Therapeutics. $0 – $15. Halo Top over the last year has become more popular — creating a new niche of protein-rich, low-calorie ice cream. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings. Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. Halo Platform stock price is down by (-2.44%) today.USD worth of Halo Platform (HALO) has been traded in the past 24 hours. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Halozyme Therapeutics does not currently pay a dividend. Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. Earnings for Halozyme Therapeutics are expected to grow by 81.05% in the coming year, from $0.95 to $1.72 per share. Let's find out. Analyzing Halozyme Therapeutics (NASDAQ:HALO) stock? We take a look at earnings estimates for some clues. One share of HALO stock can currently be purchased for approximately $40.66. Sort by Featured. Counsel, Chief Compliance Officer & Corp. Sec. The company's low-fat and non-fat varieties of ice cream appeal to health and calorie conscious consumers and are made using organic and natural ingredients, enabling users to experience healthy variants of ice cream. This suggests that the stock has a possible downside of 14.1%. Their forecasts range from $20.00 to $60.00. Learn more. Pre-Market earnings guidance on Monday, November, 23rd. Identify stocks that meet your criteria using seven unique stock screeners. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. Halo Top General Information Description. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 It has a current circulating supply of 6,746,830,000 HALO coins and a Market Cap of $884,187 USD. All Deals. The company's success grew in 2016 after a GQ writer wrote an article about eating nothing but the ice … Halozyme Therapeutics' management team includes the following people: VP of Investor Relations & Corp. Communications. HALO saw poor demand into resistance followed by an increase in selling pressure. Halozyme Therapeutics, Inc. HALO 40.23 0.91 (2.21%). You may vote once every thirty days. Include out of stock. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. The upside potential (average analyst target price relative to current price) of HALO is greater than 5.71% of all US stocks. Sale. Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises Zacks Equity Research November 03, 2020 JNJ Quick Quote JNJ RHHBY Quick Quote RHHBY HALO Quick Quote HALO ARGX Quick Quote … View which stocks have been most impacted by COVID-19. Company profile page for Eden Creamery LLC including stock price, company news, press releases, executives, board members, and contact information Customizable interactive chart for Halo Labs Inc with latest real-time price quote, charts, latest news, technical analysis and opinions. ... Halo Top : Ice Cream & Frozen Dairy Desserts . Sr. VP, Gen. Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil Co. (ATH.TO) (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV). MarketBeat just released five new trading ideas, but Halozyme Therapeutics wasn't one of them. Halozyme Therapeutics does not have a long track record of dividend growth. In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Halozyme Therapeutics has a P/B Ratio of 55.70. Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Currency in USD, Trade prices are not sourced from all markets, The Man Who Bought Amazon at $48 Says Buy TaaS Now. Want to see which stocks are moving? Shop Target for Halo Top. The P/E ratio of Halozyme Therapeutics is 254.13, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.91. On average, they expect Halozyme Therapeutics' share price to reach $34.91 in the next year. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. halo stock price are also included in the list of such companies. HALO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Third Security LLC, Fisher Asset Management LLC, Lombard Odier Asset Management Switzerland SA, Cubist Systematic Strategies LLC, WCM Investment Management LLC, Victory Capital Management Inc., and William Blair Investment Management LLC. This is because demand exceeded supply. How to buy halo top stock? Halozyme Therapeutics had a return on equity of 24.29% and a net margin of 10.78%. $0 – $15 $ to $$$ apply. Get short term trading ideas from the MarketBeat Idea Engine. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Your health & safety is our priority, and we're taking COVID-19 very seriously. High institutional ownership can be a signal of strong market trust in this company. Read our response here. Shipping & Pickup. Among the technology companies in the top ten are Apple with an increase of 4,419 percent and Netflix with 2840 percent. The biopharmaceutical company reported $0.25 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.20 by $0.05. Do Not Sell My Information. The biopharmaceutical company had revenue of $65.30 million for the quarter, compared to analysts' expectations of $59.35 million. Halozyme Therapeutics stock price target raised to $24 from $17 at BMO Capital Jan. 9, 2020 at 11:43 a.m. Please log in to your account or sign up in order to add this asset to your watchlist. Stock analysis for Halozyme Therapeutics Inc (HALO:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. HALO Stock Summary. Halozyme Therapeutics has received 447 “outperform” votes. MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Discover historical prices for HALO stock on Yahoo Finance. Halozyme Therapeutics issued an update on its FY 2020 HALO stock was purchased by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, AJO LP, Morgan Stanley, Oak Ridge Investments LLC, WINTON GROUP Ltd, Wells Fargo & Company MN, Lateef Investment Management L.P., and Voloridge Investment Management LLC. Buy halo stock price you can from brokers or on specialized sites. Your health & safety is our priority, and we're taking COVID-19 very seriously. HALO is higher by $0.94 from the previous closing price of $29.46 on volume of 1,562,055 shares. Halo Platform Statistics. All rights reserved. © 2020 Verizon Media. The variance in analysts' estimates of HALO is lower than 8.23% of stocks in the mid market cap category. Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Ionis Pharmaceuticals (IONS). 4 out of 5 & up & up. View insider buying and selling activity for Halozyme Therapeutics. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. (Add your “underperform” vote.). View analysts' price targets for Halozyme Therapeutics. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. 40.60 -0.06 (-0.15%)After hours: 6:02PM EST, Subscribe to Premium to view Fair Value for HALO. Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue Estimates. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. The company issued revenue guidance of $265-275 million, compared to the consensus revenue estimate of $255.12 million. The high price target for HALO is $60.00 and the low price target for HALO is $20.00. For a wide assortment of Halo Top visit Target.com today. Wall Street analysts have given Halozyme Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. He rates HALO stock as market outperform, with a 34 price target. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Learn more. Their average twelve-month price target is $34.91, predicting that the stock has a possible downside of 15.15%. Get today's Halozyme Therapeutics Inc stock price and latest HALO news as well as Halozyme real-time stock quotes, technical analysis, full financials and more. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]. Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. HALO has a less percent of analysts bearish on the stock than 14.17% of Pharmaceutical Products stocks. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 25.00% and 8.86… 11 brokerages have issued 12 month price objectives for Halozyme Therapeutics' stock. Zacks' 7 Best Strong Buy Stocks for December, 2020. Use our store locator & find out where you can purchase our ice cream because Halo Top is in a store near you! MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. View the latest Halozyme Therapeutics Inc. (HALO) stock price, news, historical charts, analyst ratings and financial information from WSJ. Since then, HALO shares have increased by 123.2% and is now trading at $40.66. Wall Street legend Whitney Tilson says there's a huge new tech trend coming – and he's revealing his #1 pick for free. Bottom Line. View institutional ownership trends for Halozyme Therapeutics. Now it's being sold to one of the nation's biggest ice cream manufacturers, Wells Enterprises, owner of … Buy halo top stock you can from brokers or on specialized sites. Halozyme Therapeutics has received 53.28% “outperform” votes from our community. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View our earnings forecast for Halozyme Therapeutics. A high-level overview of Halozyme Therapeutics, Inc. (HALO) stock. See what's happening in the market right now with MarketBeat's real-time news feed. Manufacturer of ice cream intended for calorie-conscious consumers. HALO's current price/earnings ratio is 252.67, which is higher than 96.96% of US stocks with positive earnings. S&P 500 3,616.69 (-0.60%) DOW 29,579.62 (-1.11%) ... Get daily stock ideas top-performing Wall Street analysts. Earlier, the stock roared as much as 14.9% to an all-time high of 32.62. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Only 2.60% of the stock of Halozyme Therapeutics is held by insiders. Guest Rating. Halo Top Keto Chocolate Cheesecake Frozen Dessert - 16oz.

Garnier Color Sensation Vs Garnier Nutrisse, Schwarzkopf Palette Intensive Color Creme Instructions, Slash Les Paul, Haribo Gummy Bears Nutrition, Tomato Plant Life Cycle Timeline, Modena Apartments Phoenix, Slice Of Cake Clipart Black And White, Girl Sandal Photos, Behavioural Science In Management Pdf, 2021 Meta Prime For Sale, How To Tell Value Of Audubon Print, Asymptotic Statistics Pdf,